Integra LifeSciences (IART) – Research Analysts’ Recent Ratings Updates

Integra LifeSciences (NASDAQ: IART) has recently received a number of price target changes and ratings updates:

• 5/13/2026 – Integra LifeSciences was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/9/2026 – Integra LifeSciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/6/2026 – Integra LifeSciences had its price target raised by Citigroup Inc. from $9.00 to $11.00. They now have a “sell” rating on the stock.
• 5/6/2026 – Integra LifeSciences had its price target raised by Wells Fargo & Company from $12.00 to $15.00. They now have an “equal weight” rating on the stock.
• 4/15/2026 – Integra LifeSciences had its price target lowered by Truist Financial Corporation from $13.00 to $12.00. They now have a “hold” rating on the stock.
• 4/15/2026 – Integra LifeSciences had its “hold” rating reaffirmed by Argus.
• 3/27/2026 – Integra LifeSciences had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 3/18/2026 – Integra LifeSciences was upgraded by Wells Fargo & Company to “hold”.

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.